Schistosomiasis (Bilharzia)

1. Clinical Overview

Summary

Schistosomiasis is a chronic parasitic disease caused by blood flukes (trematodes) of the genus Schistosoma. It ranks as the second most devastating parasitic disease globally after malaria, affecting over 240 million people with an estimated 700 million at risk in 78 endemic countries. [1,2] The disease causes approximately 200,000 deaths annually, predominantly in sub-Saharan Africa. [3]

Infection occurs via percutaneous penetration of cercariae (larval forms) released from infected freshwater snails during contact with contaminated water bodies. The clinical spectrum spans three distinct phases: cercarial dermatitis ("swimmer's itch"), acute schistosomiasis (Katayama fever), and chronic schistosomiasis characterized by granulomatous inflammation secondary to tissue-trapped ova.

The two predominant clinical syndromes are urogenital schistosomiasis (caused by S. haematobium) and intestinal/hepatosplenic schistosomiasis (caused by S. mansoni, S. japonicum, S. mekongi, and S. intercalatum). [4]

Key Facts

Global Distribution:
- S. haematobium: 53 countries across Africa and Middle East. Lake Malawi represents a well-documented transmission hotspot for travelers.
- S. mansoni: 55 countries in sub-Saharan Africa, Middle East, Caribbean (St. Lucia, Suriname), and South America (Brazil, Venezuela).
- S. japonicum: China, Philippines, Indonesia (most pathogenic species; single female produces 3,000 eggs/day vs 300 for other species). [5]
- S. mekongi: Mekong River basin (Laos, Cambodia).
- S. intercalatum: Central and West Africa (rare).
Species-Specific Egg Morphology:
- S. haematobium: Terminal spine; found in urine (10am-2pm peak excretion).
- S. mansoni: Lateral spine; found in stool.
- S. japonicum: Rudimentary/absent spine, smaller size; found in stool.
- S. mekongi: Similar to S. japonicum but larger.
- S. intercalatum: Terminal spine (longer than S. haematobium).
Carcinogenesis: Chronic S. haematobium infection is classified as Group 1 carcinogen by IARC (International Agency for Research on Cancer) for squamous cell carcinoma of the bladder, contrasting with the urothelial (transitional cell) carcinoma associated with smoking and aromatic amine exposure. [6]

Clinical Pearls

The "Midday Urine" Rule: S. haematobium egg excretion demonstrates diurnal variation with peak shedding between 10:00 and 14:00. Collection of terminal stream urine during this window, preceded by light exercise (jumping, stair climbing), significantly enhances diagnostic yield. [7]

Katayama Management Paradox: Acute schistosomiasis (Katayama fever) requires corticosteroids as first-line therapy (prednisolone 40mg daily for 5 days). Immediate praziquantel administration can precipitate life-threatening immune complex-mediated reactions due to massive antigen release from dying worms. Delayed praziquantel (given at 4-6 weeks when worms mature) prevents this Jarisch-Herxheimer-like phenomenon. [8]

The "Diagnostic Window": Serology becomes positive 6-8 weeks post-exposure (timing of seroconversion). Microscopy detects eggs from 8-12 weeks post-infection (onset of oviposition). Testing symptomatic travelers immediately post-return yields false negatives. Optimal screening occurs at 3 months post-exposure for definitive diagnosis. [9]

Preserved Hepatocellular Function: Unlike cirrhosis, hepatosplenic schistosomiasis causes presinusoidal portal hypertension via Symmers' periportal (pipe-stem) fibrosis. Hepatocellular synthetic function remains intact despite massive portal pressures and splenomegaly. Biochemistry shows normal albumin, normal coagulation, and normal bilirubin—only portal hypertensive sequelae manifest. [10]

2. Epidemiology

Global Burden

Schistosomiasis represents a disease of poverty and inadequate water, sanitation, and hygiene (WASH) infrastructure. The 2021 Global Burden of Disease study estimates 251.4 million prevalent cases with 3.31 million disability-adjusted life years (DALYs). [1] Sub-Saharan Africa bears 90% of the global burden, with Nigeria, Tanzania, Ghana, Madagascar, and Mozambique accounting for over 50% of cases requiring preventive chemotherapy. [2]

School-aged children (5-14 years) experience peak prevalence and intensity of infection due to high-risk water contact behaviors (swimming, bathing, fishing). Gender differences emerge post-puberty: males predominate in S. haematobium infections (agricultural/fishing activities), while females show higher S. mansoni rates in regions where domestic water collection falls to women. [11]

Transmission Dynamics

Definitive Host: Humans (all five species); S. japonicum and S. mekongi exhibit zoonotic potential with reservoir hosts including water buffalo, cattle, dogs, and rodents.

Intermediate Hosts: Species-specific freshwater snails:

Bulinus species → S. haematobium, S. intercalatum
Biomphalaria species → S. mansoni
Oncomelania species → S. japonicum
Neotricula aperta → S. mekongi

Environmental Requirements:

Freshwater bodies with temperature 20-30°C (cercarial activity peaks at 25-28°C)
Slow-moving or stagnant water (lakes, irrigation canals, dams, rice paddies)
pH 6.0-8.0
Presence of aquatic vegetation (snail habitat)
Fecal/urinary contamination from open defecation/urination practices

High-Risk Populations:

Agricultural workers (rice cultivation, irrigation activities)
Fishermen and their families
Women performing domestic water collection and laundry
Children engaging in recreational water activities
Travelers to endemic regions (adventure tourism, freshwater exposure)

Seasonality: Transmission peaks during dry season when water contact intensifies at shrinking permanent water sources, and during agricultural cycles (planting/harvesting in flooded fields). [12]

Non-Transmission Routes

Critical teaching point: Schistosomiasis is NOT transmitted by:

Drinking contaminated water (gastric acid kills cercariae; theoretical buccal mucosa penetration risk minimal)
Person-to-person contact
Saltwater/marine environments (snails are freshwater)
Brief water contact less than 10 minutes (exposure-response relationship exists; risk increases with duration)

3. Pathophysiology

Complete Life Cycle

Stage 1: Environmental Phase

Infected humans excrete schistosome eggs in urine (S. haematobium) or feces (S. mansoni, S. japonicum, S. mekongi, S. intercalatum). Upon contact with freshwater, eggs hatch releasing miracidia (ciliated larvae) which survive 8-12 hours seeking specific snail hosts. Miracidia penetrate snail tissue, undergo asexual reproduction producing sporocysts, which generate thousands of cercariae over 4-6 weeks. [13]

Cercariae exhibit positive phototaxis and negative geotaxis (swimming toward light, away from bottom), concentrating at water surface during peak sunlight hours. Each cercaria possesses a bifurcated tail for motility and cephalic glands secreting proteolytic enzymes. Cercariae demonstrate chemotaxis toward skin lipids and remain infectious for 48-72 hours post-release. [14]

Stage 2: Skin Penetration (Minutes to Hours)

Cercariae attach to human skin via ventral sucker, secrete elastases and glycosidases degrading the stratum corneum, and burrow through epidermis within 5-15 minutes. During penetration, cercariae shed their bifurcated tails transforming into schistosomula. This transformation involves tegumental surface membrane replacement making them resistant to antibody-complement attack. [15]

Cercarial Dermatitis: Immediate type IV hypersensitivity reaction to cercarial antigens and penetration trauma causes "swimmer's itch"—pruritic, maculopapular eruption appearing within hours, resolving in 3-7 days. Severe reactions occur with repeated exposures (sensitization).

Stage 3: Migration and Maturation (Weeks 3-6)

Schistosomula enter dermal capillaries/lymphatics, transit to lungs (trapped in pulmonary capillaries for 3-4 days undergoing physiological maturation), then migrate to hepatic portal system arriving by day 7-10. Within liver sinusoids, schistosomula mature into adult worms over 3-4 weeks, developing into sexually dimorphic forms. [16]

Sexual Pairing: Male worms (10-20mm length, robust) possess a ventral gynecophoric canal housing the longer, thinner female (15-25mm). Permanent pairing is obligatory for female sexual maturation and oviposition. Paired worms migrate against portal blood flow to species-specific target venous plexuses:

S. haematobium → Vesical, prostatic, uterine venous plexuses
S. mansoni → Inferior mesenteric veins (rectosigmoid predominance)
S. japonicum → Superior and inferior mesenteric veins
S. mekongi → Mesenteric veins
S. intercalatum → Hemorrhoidal plexus

Stage 4: Oviposition and Tissue Pathology (Weeks 6-12 onward)

Females begin egg production 4-6 weeks post-infection, producing 300-3,000 eggs daily (species-dependent) for their 3-7 year lifespan. Eggs possess species-specific spines and secretory glands producing proteolytic enzymes facilitating tissue migration. Approximately 50% of eggs traverse the vascular endothelium, bladder wall, or intestinal mucosa to reach excretory lumens (urine/feces), propagating transmission. [17]

The remaining 50% of eggs become trapped in submucosal tissues or embolize to liver (via portal circulation) and lungs (via portosystemic collaterals). Trapped eggs secrete soluble egg antigens (SEA) triggering intense CD4+ Th2-mediated granulomatous inflammation. Initial granulomas (acute phase) measure 200-400μm diameter composed of eosinophils, macrophages, lymphocytes, and multinucleated giant cells surrounding eggs. [18]

Chronic Fibrosis: Over months to years, granulomas undergo down-modulation (immunological tolerance) reducing to 50μm diameter, but cumulative collagen deposition results in:

Symmers' periportal fibrosis (hepatosplenic disease): Pathognomonic "clay pipe-stem" appearance from concentric periportal collagen deposition preserving hepatocellular parenchyma
Bladder wall fibrosis (urogenital disease): "Sandy patches" of calcified egg granulomas visible on cystoscopy
Intestinal pseudopolyps: Granulomatous masses protruding into bowel lumen
Pulmonary arteritis: Cor pulmonale from chronic egg embolization

Immunopathogenesis

Acute Phase (Weeks 3-8): Massive egg deposition triggers systemic immune activation with polyclonal B-cell stimulation, immune complex formation, and eosinophil recruitment. Cytokine storm (IL-4, IL-5, IL-13) characterizes Katayama syndrome with potential Type III hypersensitivity manifestations. [19]

Chronic Phase (Months to Years): Th2 polarization persists but granuloma size decreases via:

IL-10 production (regulatory T cells)
Blocking antibodies (IgG4, IgM)
Antigen-specific immune tolerance
Schistosome-derived immunomodulatory molecules

Paradoxical Protective Immunity: Partial immunity develops after years of infection, reducing worm burdens and pathology. Epidemiological studies demonstrate age-intensity curves peaking in childhood then declining—attributed to acquired resistance rather than reduced water contact. IgE and IgG1 responses to schistosome antigens correlate with protection. [20]

4. Clinical Presentation

Stage 1: Cercarial Dermatitis (Hours to Days Post-Exposure)

"Swimmer's Itch": Immediate pruritic, erythematous, maculopapular rash at penetration sites (ankles, feet, legs, trunk depending on immersion depth). Lesions appear 2-6 hours post-exposure, peak at 24-48 hours, resolve within 5-7 days without scarring.

Severity correlates with:

Intensity of cercarial exposure
Prior sensitization (more severe with repeated exposures)
Individual immune responsiveness

Differential Diagnosis: Insect bites, allergic contact dermatitis, sea lice (seabather's eruption from jellyfish larvae—occurs in saltwater, not freshwater).

Stage 2: Acute Schistosomiasis (Katayama Fever) - Weeks 2-8

Pathophysiology: Serum sickness-like syndrome triggered by massive egg deposition and immune complex formation. Occurs more frequently in non-immune travelers than endemic population residents (tolerance in repeatedly exposed individuals).

Clinical Features:

Fever: High-grade (38-40°C), continuous or spiking pattern
Urticarial Rash: Migratory wheals, angioedema
Respiratory: Dry cough, dyspnea, wheeze (pulmonary infiltrates)
Gastrointestinal: Abdominal pain, diarrhea (may be bloody), nausea
Hepatosplenomegaly: Tender hepatomegaly, splenomegaly
Lymphadenopathy: Generalized lymph node enlargement

Laboratory Hallmarks:

Marked eosinophilia (20-60%; absolute count often > 3,000/μL)
Elevated IgE (total and schistosome-specific)
Elevated inflammatory markers (ESR, CRP)
Mild transaminase elevation
Positive serology (IgM may be positive; IgG may still be negative early)
Negative ova microscopy (too early for egg production)

Severe Katayama: Rarely progresses to:

Meningoencephalitis (headache, altered consciousness, seizures)
Myocarditis
Glomerulonephritis (immune complex deposition)
Diffuse alveolar hemorrhage

Stage 3: Chronic Schistosomiasis (Months to Years)

A. Intestinal Schistosomiasis (S. mansoni, S. japonicum, S. mekongi, S. intercalatum)

Gastrointestinal Manifestations:

Bloody Diarrhea: Chronic or intermittent; dysentery-like syndrome (mucoid, bloody stools with tenesmus)
Abdominal Pain: Colicky, lower abdominal cramping
Inflammatory Polyps: Granulomatous masses visible on colonoscopy (differential includes IBD, colorectal cancer)
Protein-Losing Enteropathy: Hypoalbuminemia from mucosal exudation
Intestinal Obstruction: Rare complication from massive polyposis or stricture
Perforation: Life-threatening complication (especially S. japonicum with high egg burdens)

Endoscopic Findings:

Mucosal granularity, friability, ulceration
"Sandy patches" (submucosal egg deposition)
Pseudopolyps (hyperplastic inflammatory polyps)
Strictures (chronic fibrosis)

B. Hepatosplenic Schistosomiasis

Symmers' Periportal Fibrosis:

Pathognomonic: "Clay pipe-stem fibrosis"—white fibrous thickening radiating from portal triads visible on liver surface (autopsy/surgical specimens)
Mechanism: Eggs embolize from mesenteric veins to portal venules, triggering periportal granulomas and concentric fibrosis

Presinusoidal Portal Hypertension: Unlike cirrhosis, obstruction occurs before hepatic sinusoids, preserving hepatocellular function while causing:

Massive Splenomegaly: Often extends to right iliac fossa (differential includes malaria, lymphoma, myelofibrosis)
Hypersplenism: Pancytopenia (thrombocytopenia most prominent)
Esophageal Varices: High-risk for life-threatening hemorrhage
Gastric Varices: Often co-exist
Ascites: Develops in advanced disease despite normal albumin (portal hypertension-mediated)
Caput Medusae: Dilated periumbilical collaterals

Preserved Liver Function:

Normal or mildly elevated transaminases
Normal albumin, bilirubin, INR (until very advanced)
Child-Pugh Class A despite severe portal hypertension
Liver biopsy shows periportal fibrosis with intact lobular architecture

Glisson's Capsule Thickening: Palpable nodular, irregular liver edge (differs from smooth hepatomegaly of fatty liver or cirrhotic nodularity).

C. Urogenital Schistosomiasis (S. haematobium)

Bladder Manifestations:

Painless Terminal Hematuria: Classic presentation (blood at end of urinary stream)
Dysuria, Frequency, Urgency: Bladder irritation symptoms
Chronic Bacterial UTI: Secondary infection of damaged mucosa
"Sandy Patches": Pathognomonic cystoscopic finding—yellowish granulomas with calcified eggs in bladder mucosa
Bladder Calcification: Visible on plain radiograph (curvilinear calcification outlining bladder wall)
Bladder Fibrosis: Reduced capacity ("thimble bladder"), vesicoureteral reflux

Upper Urinary Tract Complications:

Hydroureter, Hydronephrosis: Ureteric fibrosis/stricture causing obstruction
Chronic Kidney Disease: Obstructive uropathy progressing to ESRD
Ureteric Calculi: Nidus formation on calcified eggs

Genital Schistosomiasis:

Female: Cervicitis, cervical/vaginal granulomas ("sandy patches"), chronic pelvic pain, infertility, increased HIV transmission risk (mucosal inflammation facilitates viral entry) [21]
Male: Prostatitis, seminal vesiculitis, hemospermia, epididymo-orchitis, infertility

Bladder Carcinoma:

Squamous Cell Carcinoma (70-90% of S. haematobium-associated cancers vs. less than 5% in non-endemic regions)
Pathogenesis: Chronic inflammation, nitrosamine formation, genetic alterations (p53 mutations)
Presentation: Macroscopic hematuria, bladder mass, pelvic pain
Age: Younger than typical bladder cancer (40s-50s vs. 60s-70s)
Prognosis: Often diagnosed late-stage; poor outcomes [6]

D. Pulmonary Schistosomiasis

Acute Pulmonary: Katayama fever-associated eosinophilic pneumonitis with infiltrates, cough, dyspnea.

Chronic Cor Pulmonale:

Mechanism: Eggs/worms embolize to pulmonary arteries (via portosystemic collaterals from portal hypertension), causing granulomatous pulmonary arteritis, vascular remodeling, and pulmonary hypertension
Clinical: Progressive dyspnea, right heart failure (JVP elevation, peripheral edema, hepatomegaly)
Echocardiography: Elevated pulmonary artery pressures, RV dilatation/dysfunction
Chest CT: Mosaic attenuation, dilated pulmonary arteries, peripheral granulomas

E. Neuroschistosomiasis

Spinal Cord Involvement (Most Common Neurological Manifestation):

Pathogenesis: Ectopic egg deposition in spinal cord (venous plexus communication via Batson's plexus) or aberrant worm migration
Species: S. mansoni (conus medullaris/cauda equina) > S. haematobium > S. japonicum
Presentation: Acute/subacute transverse myelitis, cauda equina syndrome
- Lower extremity weakness, numbness
- Bladder/bowel dysfunction (urinary retention, incontinence)
- Sensory level
MRI: T2 hyperintense intramedullary lesions, enhancement with gadolinium, cord expansion
CSF: Eosinophilic pleocytosis (though may be absent), elevated protein
Diagnosis: Clinical suspicion + compatible imaging + positive serology (eggs rarely detected in CSF)

Cerebral Schistosomiasis (Rare):

Pathogenesis: S. japonicum (produces smaller eggs capable of traversing pulmonary capillaries and reaching cerebral circulation)
Presentation: Seizures, focal neurological deficits, headache, altered consciousness
Imaging: Multiple ring-enhancing lesions (differential includes neurocysticercosis, tuberculoma, toxoplasmosis)

5. Clinical Examination

General Inspection

Nutritional status: Chronic disease may cause growth stunting (children), cachexia (adults)
Jaundice: Absent (unless concurrent hepatitis or advanced liver disease)
Anemia: Pallor from chronic blood loss, hypersplenism

Abdominal Examination

Inspection:

Distension: Ascites (advanced hepatosplenic disease)
Caput medusae: Dilated periumbilical collaterals (portal hypertension)
Surgical scars: Prior variceal bleeding intervention

Palpation:

Hepatomegaly: Firm, irregular, nodular edge (Symmers' fibrosis); liver may be normal size or mildly enlarged
Splenomegaly: Ranges from palpable spleen tip to massive splenomegaly reaching right iliac fossa
- "Measurement: Record distance below left costal margin (cm) and from umbilicus"
- "Characteristics: Firm, non-tender, moves with respiration, cannot get above it"
Ascites: Shifting dullness, fluid thrill (assess for stigmata of portal hypertension vs. peritoneal disease)

Percussion: Shifting dullness (ascites)

Auscultation: Venous hum (epigastrium—portosystemic collaterals)

Cardiovascular Examination

JVP elevation: Right heart failure (cor pulmonale)
Parasternal heave: RV hypertrophy
Loud P2, TR murmur: Pulmonary hypertension, tricuspid regurgitation
Peripheral edema: Right heart failure, hypoalbuminemia (late-stage)

Respiratory Examination

Tachypnea, hypoxia: Pulmonary schistosomiasis, cor pulmonale
Bibasal crackles: Pulmonary edema (right heart failure)

Neurological Examination

Lower limb weakness: Spinal cord schistosomiasis (assess power, tone, reflexes, plantars)
Sensory level: Transverse myelitis (pinprick, light touch testing)
Bladder dysfunction: Palpable bladder (retention), incontinence
Focal deficits: Cerebral schistosomiasis (rare)

Dermatological Examination

Cercarial dermatitis: Maculopapular rash (water-exposed areas)
Excoriation: Pruritus from urticaria (Katayama fever)

6. Investigations

Parasitological Diagnosis (Gold Standard)

Urine Microscopy (S. haematobium)

Specimen Collection:

Timing: 10:00-14:00 (peak egg excretion)
Type: Terminal stream urine (final 10ml voided)
Pre-collection exercise: Jumping, running, stair-climbing (enhances bladder wall egg dislodgement)

Technique:

Filtration method: 10ml urine through polycarbonate filter (pore size 12-20μm), stain with iodine, examine microscopically
Sensitivity: 70-90% (single specimen); improves with 3 consecutive daily specimens

Egg Morphology:

S. haematobium: 110-170μm × 40-70μm; terminal spine; viable eggs contain miracidium (motile within egg)

Quantification: Eggs per 10ml urine (infection intensity grading per WHO):

Light: less than 50 eggs/10ml
Heavy: ≥50 eggs/10ml

Stool Microscopy (S. mansoni, S. japonicum, S. mekongi, S. intercalatum)

Technique:

Kato-Katz thick smear: 41.7mg stool (template-measured) pressed under cellophane soaked in glycerol/malachite green, examined after 30-60 min clearing
Sensitivity: 70-90% (single specimen); 3 specimens over 3 days increases yield
Formol-ether concentration: Alternative method

Egg Morphology:

S. mansoni: 114-175μm × 45-70μm; prominent lateral spine
S. japonicum: 70-100μm × 50-65μm; small/absent spine, round
S. mekongi: 51-73μm × 39-66μm; small lateral knob
S. intercalatum: 140-240μm × 50-85μm; terminal spine (longer than S. haematobium)

Quantification: Eggs per gram (epg) of feces (WHO intensity grading):

S. mansoni: Light less than 100 epg; Moderate 100-399 epg; Heavy ≥400 epg
S. japonicum: Light less than 100 epg; Moderate 100-399 epg; Heavy ≥400 epg

Tissue Biopsy

Indications: Microscopy-negative with high clinical suspicion

Rectal Biopsy ("Rectal Snip"):

Technique: Mucosal biopsy (avoiding submucosal vessels) from rectosigmoid junction using rigid proctoscopy
Processing: "Squash preparation"—tissue compressed between glass slides, examined for eggs
Sensitivity: 80-90% for S. mansoni; detects eggs in rectal mucosa even without overt intestinal symptoms

Bladder Biopsy:

Cystoscopy: Visualize "sandy patches" (calcified granulomas), ulcers, polyps, masses
Biopsy: Confirms active infection (eggs with miracidia) vs. inactive (calcified eggs only)
Utility: Differentiates schistosomiasis from bladder malignancy

Serological Diagnosis

Antibody Detection

Assays:

ELISA (enzyme-linked immunosorbent assay): Detects IgG to schistosome antigens
Immunoblot: Confirms positive ELISA; identifies species-specific antibodies
Rapid diagnostic tests: Point-of-care lateral flow assays (emerging technology)

Interpretation:

Positive serology: Indicates current or past infection (cannot distinguish); antibodies persist for years post-treatment
Negative serology: Rules out infection if > 3 months post-exposure
Utility: High sensitivity (95-100%) in travelers; less useful in endemic populations (high background seropositivity)

Limitations:

Cannot assess treatment success (antibodies persist)
Cannot quantify infection intensity
Cross-reactivity with other helminths (minimal with purified antigens)

Antigen Detection

Circulating Cathodic Antigen (CCA):

Urine-based rapid test (lateral flow cassette)
Detection: Schistosome gut-associated antigen (produced by living worms)
Species: Detects S. mansoni (also S. haematobium with reduced sensitivity)
Advantages: Point-of-care, distinguishes active infection, becomes negative post-treatment
Sensitivity: 80-95% for S. mansoni; superior to Kato-Katz in low-intensity infections
Limitations: Semi-quantitative (trace positives ambiguous), S. japonicum not detected [22]

Circulating Anodic Antigen (CAA):

Serum-based assay
Detection: Schistosome antigen
Advantages: Highly sensitive, quantifiable, detects all species
Limitations: Requires laboratory infrastructure, not widely available

Hematology and Biochemistry

Full Blood Count:

Eosinophilia: Acute schistosomiasis (20-60%); chronic infection (mild 5-15% or absent)
Anemia: Normocytic (chronic disease), iron-deficiency (chronic GI blood loss)
Thrombocytopenia: Hypersplenism
Leukopenia: Hypersplenism (advanced hepatosplenic disease)

Liver Function Tests:

Transaminases: Normal or mildly elevated (ALT/AST less than 2× ULN)
Albumin: Normal until very advanced (contrast with cirrhosis)
Bilirubin: Normal (unless complications)
INR: Normal (preserved synthetic function)
Alkaline phosphatase: May be mildly elevated (granulomatous inflammation)

Renal Function:

Creatinine elevation: Obstructive uropathy (urogenital schistosomiasis)
Urinalysis: Hematuria (gross or microscopic), proteinuria, pyuria (secondary UTI)

Inflammatory Markers:

ESR, CRP: Elevated in acute schistosomiasis; mild elevation in chronic disease

Imaging

Ultrasound (First-Line Imaging)

Abdominal Ultrasound (WHO Niamey Protocol for Hepatosplenic Schistosomiasis):

Liver Parenchyma:
- "Pattern A-C: Normal variants"
- "Pattern D: Echogenic thickening around small portal vein branches (early periportal fibrosis)"
- Pattern E: Extensive echogenic "pipe-stem" bands around portal veins (Symmers' fibrosis)
- "Pattern F: Advanced fibrosis with nodularity, contracted liver"
Portal Vein Diameter: Dilatation > 13mm indicates portal hypertension
Spleen Size: Enlargement (span > 13cm adults, age-adjusted pediatrics)
Ascites: Free fluid (portal hypertension vs. hypoalbuminemia)
Gallbladder Wall Thickening: Periportal inflammation extension

Urinary Tract Ultrasound:

Bladder Wall Thickening: > 5mm (fibrosis)
Bladder Wall Irregularity: Masses (polyps, carcinoma)
Hyperechoic Bladder Wall Foci: Calcified eggs ("sandy patches")
Hydronephrosis/Hydroureter: Obstructive uropathy
Kidney Size: Asymmetry (unilateral obstruction), bilateral small kidneys (CKD)

Radiography

Plain Abdominal X-ray:

Bladder Calcification: Curvilinear eggshell-like calcification outlining bladder wall (S. haematobium)
Ureteric Calcification: Calcified ureters
Hepatic Calcification: Rare; "turtle-back" appearance

Chest X-ray:

Acute: Diffuse interstitial infiltrates (Katayama fever eosinophilic pneumonitis)
Chronic: Cardiomegaly (cor pulmonale), pulmonary artery enlargement

Cross-Sectional Imaging

CT Abdomen/Pelvis:

Liver: Peripheral geographic areas of hypoattenuation (periportal fibrosis), calcified granulomas
Spleen: Massive splenomegaly, splenic varices
Bladder: Wall thickening, calcification, masses (SCC staging)
Portal/Splenic Vein Thrombosis: Complication assessment

MRI Abdomen:

T2-weighted: Periportal fibrosis appears hyperintense (early disease)
MRCP: Biliary tree assessment (differential diagnosis)

CT/MRI Spine/Brain (Neuroschistosomiasis):

Spinal Cord: T2 hyperintense intramedullary lesion (thoracolumbar > cervical), enhancement, cord expansion
Brain: Multiple ring-enhancing lesions (S. japonicum)

Endoscopy

Cystoscopy:

"Sandy Patches": Pathognomonic yellowish granulomas with central umbilication
Ulcers, Polyps: Inflammatory lesions
Masses: Squamous cell carcinoma (biopsy for diagnosis)
Trigone/Ureteric Orifice Involvement: Assess for obstruction

Colonoscopy/Sigmoidoscopy:

Mucosal Abnormalities: Granularity, friability, ulceration (rectosigmoid predominance for S. mansoni)
Pseudopolyps: Inflammatory polyps (biopsy to differentiate from IBD/malignancy)
Biopsy: Histology shows granulomas with eggs; "squash prep" for direct egg visualization

7. Management

Management Algorithm

                CONFIRMED/SUSPECTED SCHISTOSOMIASIS
                    (Eggs, serology, CCA+)
                             ↓
        ┌────────────────────┴────────────────────┐
      ACUTE                                    CHRONIC
  (Katayama Fever)                        (Established Infection)
        ↓                                         ↓
  SEVERE SYMPTOMS?                        ASSESS COMPLICATIONS
  (Shock, respiratory                     (Liver, bladder, CNS)
   distress, CNS)                                ↓
        ↓                                  PRAZIQUANTEL
   ┌────┴────┐                           ┌──────┴──────┐
  YES       NO                       Standard      Special Cases
   ↓          ↓                           ↓              ↓
HOSPITAL   OUTPATIENT                 40mg/kg      CNS: 60mg/kg
  ↓          ↓                         Single       + STEROIDS
PREDNISOLONE 40-60mg                   dose        Repeat 4-6 wks
  Daily × 5-7 days                  S. japonicum:      ↓
  ↓                                  60mg/kg ÷2    POST-TREATMENT
Add Praziquantel                         ↓         MONITORING
at 4-6 weeks                     CURE ASSESSMENT   (See below)
(worm maturation)                  (3-6 months)

1. Antiparasitic Therapy

Praziquantel (Drug of Choice)

Mechanism of Action:

Increases cell membrane permeability to calcium ions → tetanic muscular contraction → paralysis and detachment of worms from vascular endothelium
Tegumental disruption → exposure of worm antigens → immune-mediated destruction
No activity against immature schistosomula (less than 4 weeks old)

Dosing:

S. haematobium, S. mansoni, S. intercalatum: 40 mg/kg PO single dose (or 20mg/kg × 2 doses 4-6 hours apart)
S. japonicum, S. mekongi: 60 mg/kg PO divided (20mg/kg × 3 doses or 30mg/kg × 2 doses, 4-6 hours apart) [due to lower drug susceptibility]
Neuroschistosomiasis: 60mg/kg/day × 3 days (higher dose, prolonged course)

Timing Considerations:

Ineffective during pre-patent period (less than 4-6 weeks post-infection when worms are immature)
Repeat treatment at 4-6 weeks recommended for recent infections to eradicate newly matured worms
For chronic infections (> 3 months): single course usually sufficient

Efficacy:

Cure rates: 60-90% (single dose)
Egg reduction rates: 90-95% (even in uncured patients, worm burden dramatically reduced)

Adverse Effects (generally mild, self-limiting):

Common: Abdominal pain, nausea, diarrhea, dizziness, headache, drowsiness
Onset: Within hours of dosing
Duration: 24-48 hours
Mechanism: Worm killing and antigen release
Severe reactions: Rare; more common with high worm burdens

Contraindications:

Absolute: Hypersensitivity to praziquantel
Relative:
- Pregnancy (avoid in first trimester; use with caution in 2nd/3rd trimester if benefits outweigh risks; WHO considers acceptable)
- Breastfeeding (small amounts excreted in milk; WHO advises expressing and discarding milk for 72 hours post-treatment)
- Ocular/spinal cysticercosis (risk of inflammation and herniation with dying parasites—not schistosomiasis indication but co-infection consideration in endemic areas)

Drug Interactions:

Metabolized by CYP3A4
Reduced levels: Rifampicin, phenytoin, carbamazepine, dexamethasone (may require dose increase)
Increased levels: Azole antifungals, protease inhibitors, grapefruit juice

Alternative/Adjunctive Agents

Artemisinin Derivatives (Artemether, Artesunate):

Mechanism: Active against juvenile schistosomula (complements praziquantel's adult-only activity)
Evidence: Combination therapy (artemether + praziquantel) reduces reinfection rates in endemic areas
Limitations: Not WHO-recommended monotherapy; primarily studied for S. japonicum; concerns about antimalarial resistance development

Oxamniquine:

Species: S. mansoni only
Dose: 15-60 mg/kg PO (varies by geographic strain resistance)
Current Role: Historical alternative; largely replaced by praziquantel due to cost and species-specificity

2. Management of Acute Schistosomiasis (Katayama Fever)

Corticosteroids (First-Line for Symptomatic Relief):

Drug: Prednisolone 40-60mg PO daily (or methylprednisolone IV if severe)
Duration: 5-7 days, then taper
Rationale: Suppresses immune complex-mediated inflammation
Timing: Initiate immediately upon diagnosis

Delayed Praziquantel:

Avoid immediate treatment (worm killing releases massive antigen load exacerbating hypersensitivity)
Administer at 4-6 weeks (allows worm maturation; by this time acute symptoms resolve with steroids)
Some experts give praziquantel during steroid taper (days 5-7) if worms already mature

Supportive Care:

Antihistamines: Urticaria management (cetirizine, loratadine)
Antipyretics: Paracetamol for fever
Bronchodilators: If significant wheeze
Monitoring: Severe cases require hospitalization (shock, respiratory failure, CNS involvement)

3. Management of Chronic Complications

Hepatosplenic Schistosomiasis

Portal Hypertension:

Praziquantel: Arrests progression; does not reverse established fibrosis
Variceal Management:
- "Primary prophylaxis: Non-selective beta-blockers (propranolol, carvedilol) if large varices on endoscopy"
- "Acute hemorrhage: Resuscitation, terlipressin/octreotide, endoscopic variceal ligation (EVL) or sclerotherapy"
- "Secondary prophylaxis: Beta-blockers + repeat EVL"
Refractory Varices: Transjugular intrahepatic portosystemic shunt (TIPS)—caution: preserved liver function makes TIPS better tolerated than in cirrhosis
Surgical Shunts: Splenorenal shunt, mesocaval shunt (historical; largely replaced by TIPS)

Hypersplenism:

Observation: If asymptomatic despite thrombocytopenia (platelets > 50,000/μL)
Splenectomy: Reserved for:
- Massive symptomatic splenomegaly
- Severe hypersplenism (platelets less than 20,000/μL, bleeding complications)
- Post-operative thrombocytosis risk (lifelong aspirin)
- Overwhelming post-splenectomy infection (OPSI) risk—vaccinate (pneumococcus, meningococcus, Hib, influenza)

Urogenital Schistosomiasis

Bladder Fibrosis/Stricture:

Praziquantel: Prevents progression
Hydronephrosis:
- "Mild: Monitor renal function"
- "Moderate-severe: Ureteric stenting or surgical reimplantation"
- "Pyeloplasty: For ureteric strictures"
Recurrent UTI: Prophylactic antibiotics (nitrofurantoin, trimethoprim)

Bladder Squamous Cell Carcinoma:

Diagnosis: Cystoscopy + biopsy
Staging: CT/MRI
Treatment: Radical cystectomy (T2+), intravesical chemotherapy (superficial), radiotherapy (palliative or adjuvant)
Prognosis: Often late-stage at diagnosis (5-year survival less than 20% for muscle-invasive)

Genital Schistosomiasis:

Praziquantel: Treats active infection
Female genital schistosomiasis: Counseling regarding HIV risk, fertility issues; surgical debridement if symptomatic masses
Male genital: Antibiotics for secondary bacterial infection

Neuroschistosomiasis

Medical Management:

Praziquantel: 60mg/kg/day × 3 days (higher dose/longer duration than standard)
Corticosteroids (mandatory adjunct):
- Dexamethasone IV 8-16mg daily (severe) or Prednisolone PO 60-80mg daily
- "Duration: 2-4 weeks, then taper"
- "Rationale: Prevents inflammatory exacerbation from dying parasites"
Anticonvulsants: If seizures (levetiracetam, phenytoin)
Analgesics: For pain

Surgical Management:

Laminectomy/Decompression: If spinal cord compression with neurological deterioration despite medical therapy
Ventriculoperitoneal Shunt: If hydrocephalus (cerebral disease)

Rehabilitation:

Physiotherapy: Spinal cord injury rehabilitation
Bladder/Bowel Training: Neurogenic bladder/bowel management

Pulmonary Schistosomiasis (Cor Pulmonale)

Praziquantel: Limited benefit (established vascular remodeling irreversible)
Pulmonary Vasodilators:
- Phosphodiesterase-5 inhibitors (sildenafil, tadalafil)
- Endothelin receptor antagonists (bosentan, ambrisentan)
- Prostacyclin analogs (epoprostenol)—if severe
Diuretics: Manage fluid overload
Oxygen: If hypoxic
Anticoagulation: Controversial (bleeding risk from varices)

4. Post-Treatment Monitoring

Cure Assessment:

Timing: 3-6 months post-treatment
Methods:
- "Microscopy: Repeat urine/stool examination (egg excretion declines; absence suggests cure)"
- "CCA/CAA: Antigen tests become negative with cure (superior to antibody serology)"
- "Serology: IgG remains positive (not useful for cure assessment); IgM may decline"

Retreatment Indications:

Persistent egg excretion at 3-6 months
Persistent positive CCA/CAA
Clinical deterioration
Endemic area residents: Annual or biennial preventive chemotherapy (WHO mass drug administration programs)

Long-Term Surveillance (Chronic Complications):

Hepatosplenic: Annual liver ultrasound, upper endoscopy (variceal surveillance), CBC (hypersplenism)
Urogenital: Annual renal function, urinalysis, renal ultrasound; bladder surveillance cystoscopy (post-treatment years 1, 3, 5 then every 3-5 years) for SCC screening
Neuroschistosomiasis: MRI spine/brain at 6-12 months post-treatment; functional assessment

8. Complications

Acute Complications

Katayama Syndrome Severity:

Diffuse alveolar hemorrhage
Meningoencephalitis
Myocarditis
Acute glomerulonephritis
Death (rare; case reports)

Intestinal Perforation:

Mechanism: Massive egg burden (especially S. japonicum) causing transmural necrosis
Presentation: Acute abdomen, peritonitis
Management: Surgical resection + peritoneal lavage + praziquantel (post-operatively)

Chronic Complications

Hepatic:

Variceal hemorrhage (mortality 15-30% per episode)
Hypersplenism
Hepatopulmonary syndrome (rare)
Portopulmonary hypertension

Urogenital:

Squamous cell carcinoma (bladder): 3-14× increased risk with chronic S. haematobium [6]
Obstructive uropathy → CKD/ESRD requiring dialysis
Bladder calculi
Infertility (male/female)
HIV transmission risk: Female genital schistosomiasis increases HIV acquisition 3-4 fold (genital inflammation, mucosal breaches) [21]

Pulmonary:

Cor pulmonale (right heart failure)
Pulmonary arterial hypertension (WHO Group 5)

Neurological:

Transverse myelitis → permanent paraplegia
Cerebral granulomas → intractable epilepsy
Cognitive impairment (children with chronic infection) [23]

Nutritional:

Growth stunting (children)
Anemia (iron-deficiency, chronic disease)
Protein-losing enteropathy

Obstetric:

Increased maternal mortality (portal hypertension/variceal bleeding during labor)
Low birth weight
Preterm delivery

9. Prognosis and Outcomes

Early/Uncomplicated Infection

With Treatment:

Cure: 60-90% with single praziquantel course
Egg reduction: > 90% even in "uncured" patients (residual low-level infection)
Symptom resolution: Complete if treated before fibrosis develops
Reinfection: Common in endemic areas without improved WASH; preventive chemotherapy programs target annual/biennial treatment

Without Treatment:

Progressive fibrosis (hepatic, bladder, ureteric)
Development of complications over 5-20 years
Chronic morbidity (anemia, growth stunting, reduced work capacity)
Reduced quality of life and economic productivity

Established Complications

Hepatosplenic Schistosomiasis:

Fibrosis: Irreversible; praziquantel arrests progression but does not reverse established Symmers' fibrosis
Portal hypertension: Managed medically/endoscopically; bleeding risk persists lifelong
Liver function: Typically preserved despite portal hypertension (contrast with cirrhosis); hepatocellular carcinoma NOT a feature

Urogenital Schistosomiasis:

Bladder SCC: Poor prognosis (5-year survival 10-30% for muscle-invasive disease)
CKD: Progressive; ESRD may develop requiring renal replacement therapy
Bladder capacity: Severely contracted bladder may require augmentation cystoplasty

Neuroschistosomiasis:

Spinal cord: Variable outcomes; early treatment (before irreversible cord damage) crucial
- "Complete recovery: 30-40%"
- "Partial recovery: 30-40%"
- "No recovery/worsening: 20-30%"
Cerebral: Seizure control often achievable with anticonvulsants

Cor Pulmonale:

Progressive despite treatment
Mean pulmonary artery pressure correlates with mortality
5-year survival 50-70% with pulmonary vasodilator therapy

Population-Level Impact

Disability-Adjusted Life Years (DALYs): 3.31 million globally (2021), predominantly from:

Chronic pain and fatigue
Growth stunting and cognitive impairment (children)
Infertility
Reduced work capacity

Economic Impact: Estimated $12 billion annually in lost productivity, healthcare costs in endemic regions [24]

Control Programs: WHO targets schistosomiasis elimination as public health problem (prevalence less than 1% in school-aged children) by 2030 through:

Mass drug administration (MDA) with praziquantel
WASH improvements
Snail control
Health education

10. Prevention and Control

Individual Prevention (Travelers)

Avoidance:

Do not swim, wade, or bathe in freshwater lakes, rivers, streams in endemic areas
Even brief contact (5-10 minutes) carries risk
Safe alternatives: Chlorinated pools, seawater, water stored ≥48 hours (cercariae die)

Water Treatment (If Freshwater Exposure Unavoidable):

Heating: Heat to 50°C × 5 minutes or boil (kills cercariae)
Filtration: Filters less than 1μm pore size
Chemical: Chlorination, iodination (standard concentrations insufficient; high doses required)
UV light: Effective germicidal UV exposure

Post-Exposure:

Vigorous towel drying: Minimally effective (cercariae penetrate within minutes)
Topical application: 70% alcohol immediately post-exposure may reduce penetration (limited evidence)
Presumptive treatment: Not routinely recommended; reserved for high-risk exposure with confirmed outbreak

Chemoprophylaxis:

Not recommended (praziquantel ineffective against schistosomula; artemisinin derivatives under investigation but not WHO-approved)
Post-exposure treatment: Praziquantel 40mg/kg at 4-6 weeks AND 3 months post-exposure (kills newly matured worms)

Population-Level Control (Endemic Regions)

Mass Drug Administration (MDA)

WHO Strategy:

Target groups: School-aged children (5-14 years), high-risk adults (farmers, fishermen)
Frequency: Annual treatment if prevalence ≥50%; biennial if 10-50%; treat only confirmed cases if less than 10%
Drug: Praziquantel 40mg/kg single dose
Coverage goal: ≥75% of target population

Impact:

Reduces infection prevalence and intensity
Decreases severe morbidity
Limitations: Does not prevent reinfection; requires sustained implementation

Water, Sanitation, and Hygiene (WASH)

Interventions:

Safe water supply: Piped water, protected wells reducing freshwater body contact
Sanitation: Latrines preventing fecal/urinary contamination of water
Behavior change: Health education promoting latrine use, avoiding open defecation/urination

Snail Control

Methods:

Chemical molluscicides: Niclosamide application to water bodies (environmental concerns)
Biological control: Competitor snails, predatory fish, crustaceans
Environmental modification: Vegetation removal, water flow management reducing snail habitat
Limitations: Costly, temporary effect, ecological impact

Health Education

Community awareness campaigns
School-based education
Targeting high-risk behaviors (swimming, bathing, occupational water contact)

11. Patient and Layperson Explanation

What is Schistosomiasis (Bilharzia)?

Bilharzia is an infection caused by tiny parasitic worms that live in freshwater lakes and rivers in Africa, Asia, and South America. The worms come from infected snails.

How Did I Get It?

When you swam, bathed, or waded in contaminated fresh water, microscopic worm larvae (smaller than you can see) burrowed through your skin within minutes. They traveled through your bloodstream to your blood vessels near your intestines or bladder, where they grew into adult worms. The worms are now living in your blood vessels and laying eggs.

What Are the Symptoms?

Early (Weeks After Swimming):

You might develop a rash where the worms entered your skin
Some people get flu-like illness with fever, cough, and rash 4-8 weeks later (called Katayama fever)

Later (Months to Years):

Bladder type (most common in Africa): Blood in urine, painful urination
Intestine type: Diarrhea (sometimes bloody), stomach pain
Some people develop complications affecting the liver (causing belly swelling) or bladder (increasing cancer risk over many years)

Why is There Blood in My Urine/Stool?

The female worms lay hundreds of eggs every day. About half of these eggs become trapped in your bladder wall or intestine lining. The eggs have sharp spines that irritate the tissues, causing bleeding and inflammation as they try to escape into urine or stool.

Is It Serious?

If treated early: The infection is very treatable and most people fully recover.

If untreated: Over years, the trapped eggs cause scarring (fibrosis) that can damage your bladder, liver, or other organs. In severe cases, this can lead to serious complications.

How is It Treated?

Medication: A tablet called praziquantel kills the worms very effectively. You take it by mouth, usually as a single dose (or sometimes 2-3 doses in one day).

Side effects: You might feel nauseous or get stomach cramps for a day after taking it, but this is temporary and means the medicine is working.

Repeat treatment: If you were infected recently, your doctor may give you a second dose after 1-2 months to catch any young worms that weren't killed by the first treatment.

Will I Be Cured?

Yes! Praziquantel cures 70-90% of people with one course. Even if some worms survive, the treatment reduces them by over 90%, preventing serious complications. Your doctor will recheck urine/stool tests 3-6 months later to confirm cure.

Can I Get It Again?

Yes, if you swim in contaminated water again in countries where bilharzia exists. The treatment does not give you immunity. If you travel to or live in affected areas:

Avoid swimming or bathing in freshwater lakes, rivers, or streams
Use chlorinated pools, seawater, or treated water instead
Towel dry immediately if you do get splashed (though this doesn't fully protect you)

Special Situations

Pregnancy: Tell your doctor if you're pregnant. Praziquantel is generally safe but is sometimes delayed until after delivery unless infection is severe.

Breastfeeding: You can breastfeed, but your doctor may advise pumping and discarding milk for 3 days after treatment.

Children: The same treatment works and is safe for children.

When to Seek Urgent Medical Help

Go to the emergency department if you develop:

Vomiting blood or black tarry stools (bleeding from stomach/intestines)
Inability to urinate or severe back pain (kidney blockage)
Sudden leg weakness or numbness (rare complication affecting spinal cord)
Severe allergic reaction after starting treatment (rash, difficulty breathing)

12. References

Primary Sources

GBD 2021 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222. doi:10.1016/S0140-6736(20)30925-9
World Health Organization. Schistosomiasis: Key Facts. Updated March 2023. Accessed January 2026. https://www.who.int/news-room/fact-sheets/detail/schistosomiasis
Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet. 2014;383(9936):2253-2264. doi:10.1016/S0140-6736(13)61949-2
Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med. 2002;346(16):1212-1220. doi:10.1056/NEJMra012396
McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou XN. Schistosomiasis. Nat Rev Dis Primers. 2018;4(1):13. doi:10.1038/s41572-018-0013-8
International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 61: Schistosomes, Liver Flukes and Helicobacter pylori. Lyon, France: IARC; 1994.
Mott KE, Dixon H, Osei-Tutu E, England EC. Relation between intensity of Schistosoma haematobium infection and clinical haematuria and proteinuria. Lancet. 1983;1(8332):1005-1008. doi:10.1016/s0140-6736(83)92641-7
Harries AD, Cook GC. Acute schistosomiasis (Katayama fever): clinical deterioration after chemotherapy. J Infect. 1987;14(2):159-161. doi:10.1016/s0163-4453(87)91841-x
Whitty CJ, Mabey DC, Armstrong M, Wright SG, Chiodini PL. Presentation and outcome of 1107 cases of schistosomiasis from Africa diagnosed in a non-endemic country. Trans R Soc Trop Med Hyg. 2000;94(5):531-534. doi:10.1016/s0035-9203(00)90076-6
Andrade ZA. Schistosomiasis and liver fibrosis. Parasite Immunol. 2009;31(11):656-663. doi:10.1111/j.1365-3024.2009.01157.x
Sady H, Al-Mekhlafi HM, Mahdy MA, Lim YA, Mahmud R, Surin J. Prevalence and associated factors of schistosomiasis among children in Yemen: implications for an effective control programme. PLoS Negl Trop Dis. 2013;7(8):e2377. doi:10.1371/journal.pntd.0002377
Grimes JET, Croll D, Harrison WE, Utzinger J, Freeman MC, Templeton MR. The relationship between water, sanitation and schistosomiasis: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2014;8(12):e3296. doi:10.1371/journal.pntd.0003296
Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet. 2006;368(9541):1106-1118. doi:10.1016/S0140-6736(06)69440-3
Haas W, Haberl B, Kalbe M, Körner M. Snail-host-finding by miracidia and cercariae: chemical host cues. Parasitol Today. 1995;11(12):468-472. doi:10.1016/0169-4758(95)80067-9
Wilson RA, Coulson PS. Schistosome vaccines: a critical appraisal. Mem Inst Oswaldo Cruz. 2006;101 Suppl 1:13-20. doi:10.1590/s0074-02762006000900004
Wilson MS, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R, Wynn TA. Immunopathology of schistosomiasis. Immunol Cell Biol. 2007;85(2):148-154. doi:10.1038/sj.icb.7100014
Gryseels B. Schistosomiasis. Infect Dis Clin North Am. 2012;26(2):383-397. doi:10.1016/j.idc.2012.03.004
Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, McManus DP. Immunopathogenesis of human schistosomiasis. Parasite Immunol. 2009;31(4):163-176. doi:10.1111/j.1365-3024.2009.01098.x
Ross AG, Vickers D, Olds GR, Shah SM, McManus DP. Katayama syndrome. Lancet Infect Dis. 2007;7(3):218-224. doi:10.1016/S1473-3099(07)70053-1
Woolhouse ME, Hagan P. Seeking the ghost of worms past. Nat Med. 1999;5(11):1225-1227. doi:10.1038/15169
Kjetland EF, Leutscher PD, Ndhlovu PD. A review of female genital schistosomiasis. Trends Parasitol. 2012;28(2):58-65. doi:10.1016/j.pt.2011.10.008
Corstjens PL, De Dood CJ, Kornelis D, et al. Tools for diagnosis, surveillance and monitoring of Schistosoma infections towards control and elimination. PLoS Negl Trop Dis. 2014;8(2):e2674. doi:10.1371/journal.pntd.0002674
Ezeamama AE, Friedman JF, Olveda RM, et al. Functional significance of low-intensity polyparasite helminth infections in anemia. J Infect Dis. 2005;192(12):2160-2170. doi:10.1086/498219
King CH, Galvani AP. Underestimation of the global burden of schistosomiasis. Lancet. 2018;391(10118):307-308. doi:10.1016/S0140-6736(18)30098-9

13. Examination Focus

Common Exam Questions

MCQ/SBA Scenarios

Question 1: A 24-year-old British gap year student returns from Malawi with a 5-day history of fever, generalized urticarial rash, and dry cough. Blood tests show eosinophilia of 35%. He swam in Lake Malawi 4 weeks ago. Urine and stool microscopy are negative. What is the most likely diagnosis?

Answer: Acute schistosomiasis (Katayama fever). Timing (4 weeks post-exposure), systemic symptoms, marked eosinophilia, and negative microscopy (pre-patent period) are classic.

Question 2: Terminal stream urine microscopy reveals eggs with a terminal spine. Which species?

Answer: Schistosoma haematobium. Lateral spine = S. mansoni; rudimentary/absent spine = S. japonicum.

Question 3: A 45-year-old man from Egypt presents with hematemesis. Examination reveals massive splenomegaly to right iliac fossa and ascites. Liver function tests show normal albumin, bilirubin, and INR. Upper endoscopy shows large esophageal varices. What is the underlying pathology?

Answer: Hepatosplenic schistosomiasis with Symmers' periportal fibrosis. Presinusoidal portal hypertension with preserved hepatocellular function is pathognomonic.

Question 4: What is the mechanism of bladder cancer in chronic S. haematobium infection?

Answer: Chronic inflammation → squamous metaplasia → squamous cell carcinoma (NOT transitional cell carcinoma).

Question 5: A traveler with confirmed acute schistosomiasis (Katayama fever) is started on praziquantel. Within hours, he develops worsening fever, hypotension, and diffuse urticaria. What should have been done differently?

Answer: Corticosteroids should be given FIRST in acute schistosomiasis. Praziquantel is delayed until 4-6 weeks to avoid massive antigen release and hypersensitivity exacerbation.

OSCE/Clinical Stations

Long Case: 35-year-old Tanzanian farmer with chronic hematuria and suprapubic discomfort.

Approach:

History: Freshwater exposure (swimming, bathing, agricultural work), duration of hematuria, dysuria, constitutional symptoms
Examination: Abdominal (suprapubic mass—bladder distension?), lymphadenopathy, hepatosplenomegaly
Investigations: Urinalysis (hematuria), terminal urine microscopy (eggs), renal ultrasound (hydronephrosis?), cystoscopy (sandy patches, masses)
Differential: UTI, bladder cancer, tuberculosis, glomerulonephritis
Management: Praziquantel, assess for complications (CKD, malignancy)

Short Case: Abdominal examination reveals firm hepatomegaly and massive splenomegaly.

Presentation: "This patient has hepatosplenomegaly with a firm, irregular liver edge and spleen extending to the right iliac fossa. There is no jaundice or stigmata of chronic liver disease. The most likely diagnosis is hepatosplenic schistosomiasis causing presinusoidal portal hypertension. I would assess for complications including esophageal varices, hypersplenism, and ascites. Investigations would include liver ultrasound to assess for periportal fibrosis, upper endoscopy for varices, and schistosome serology or stool microscopy."

Viva Voce Points

Examiner: "Why is eosinophilia high in Katayama fever but often normal in chronic schistosomiasis?"

Answer: Acute schistosomiasis triggers intense Th2-mediated immune activation with IL-5-driven eosinophil recruitment in response to massive egg antigen exposure. In chronic infection, immune modulation occurs—regulatory T cells produce IL-10, "blocking antibodies" (IgG4, IgM) develop, and antigen-specific tolerance down-regulates the eosinophilic response despite ongoing egg deposition.

Examiner: "Why does hepatosplenic schistosomiasis cause portal hypertension with normal liver function?"

Answer: Schistosome eggs embolize via the portal vein to periportal venules, causing granulomatous inflammation and fibrosis around portal triads (Symmers' pipe-stem fibrosis). This creates presinusoidal obstruction to portal blood flow. The hepatocellular parenchyma (hepatocytes, sinusoids) remains intact, preserving synthetic function (albumin, clotting factors) and metabolic capacity (bilirubin conjugation). This contrasts with cirrhosis, where intrahepatic fibrosis and architectural distortion cause both portal hypertension AND hepatocellular failure.

Examiner: "Why is S. japonicum more pathogenic than other species?"

Answer: Three factors: (1) Higher egg output—females produce ~3,000 eggs/day vs. 300 for S. mansoni/haematobium, resulting in greater granuloma burden. (2) Smaller eggs—can traverse pulmonary capillaries more readily, causing cerebral schistosomiasis. (3) Zoonotic reservoir—domestic animals maintain transmission, complicating control efforts.

Examiner: "A patient presents with acute paraplegia 2 months after returning from Zimbabwe. MRI shows T2 hyperintense intramedullary cord lesion at T10. Schistosome serology is positive. How do you manage?"

Answer: Neuroschistosomiasis—medical emergency. Treatment: (1) High-dose corticosteroids (dexamethasone IV or prednisolone PO 1mg/kg) started IMMEDIATELY to prevent inflammatory cord damage. (2) Praziquantel 60mg/kg/day × 3 days (higher dose than standard) started after/with steroids. (3) Monitor neurological function closely; if deterioration despite medical therapy, consider neurosurgical decompression. (4) Rehabilitation (physiotherapy, bladder/bowel training). Prognosis depends on early treatment; 30-40% achieve complete recovery if treated before irreversible cord injury.

Examiner: "Explain the paradox: schistosomiasis causes portal hypertension but patients tolerate TIPS better than cirrhotics."

Answer: In cirrhosis, hepatocellular function is already impaired (Child-Pugh B/C). TIPS diverts portal blood away from liver, further reducing hepatic perfusion and worsening encephalopathy/synthetic dysfunction. In schistosomiasis, hepatocellular function is normal (Child-Pugh A). TIPS decompresses portal hypertension without compromising already-healthy liver function. Patients tolerate TIPS better with lower encephalopathy risk—though still present due to portosystemic shunting.

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances, local guidelines, and specialist consultation. Always verify drug dosing and contraindications before prescribing.

Clinical board

Urgent signals

Linked comparisons

Editorial and exam context